147 related articles for article (PubMed ID: 37059268)
41. Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment.
Besançon M; Gris T; Joncas FH; Picard V; Bergeron A; Fradet Y; Toren P
Eur Urol Open Sci; 2022 Sep; 43():35-44. PubMed ID: 36246841
[TBL] [Abstract][Full Text] [Related]
42. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.
Wang B; Pan W; Yang M; Yang W; He W; Chen X; Bi J; Jiang N; Huang J; Lin T
Cancer Sci; 2019 Feb; 110(2):489-498. PubMed ID: 30548363
[TBL] [Abstract][Full Text] [Related]
43. Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma.
Tang Q; Li S; Huang G; Liu H
Int Immunopharmacol; 2023 Jun; 119():110158. PubMed ID: 37062259
[TBL] [Abstract][Full Text] [Related]
44. Urine PD-L1 is a tumor tissue candidate substitute and is associated with poor survival in muscle-invasive bladder cancer patients.
Ma J; Zhou Q; Xu W; Li C; Wang H; Zhai Z; Zhang Y; Wahafu W
Int Immunopharmacol; 2023 Jan; 114():109535. PubMed ID: 36527880
[TBL] [Abstract][Full Text] [Related]
45. Androgen receptor suppresses prostate cancer metastasis but promotes bladder cancer metastasis via differentially altering miRNA525-5p/SLPI-mediated vasculogenic mimicry formation.
Yang Z; Chen J; Xie H; Liu T; Chen Y; Ma Z; Pei X; Yang W; Li L
Cancer Lett; 2020 Mar; 473():118-129. PubMed ID: 31843555
[TBL] [Abstract][Full Text] [Related]
46. The evolving role of checkpoint inhibitors in the treatment of urothelial carcinoma.
Tang G; Liu J; Qi L; Li Y
Br J Clin Pharmacol; 2023 Jan; 89(1):93-113. PubMed ID: 35997657
[TBL] [Abstract][Full Text] [Related]
47. Androgen receptor inducing bladder cancer progression by promoting an epithelial-mesenchymal transition.
Jitao W; Jinchen H; Qingzuo L; Li C; Lei S; Jianming W; Zhenli G
Andrologia; 2014 Dec; 46(10):1128-33. PubMed ID: 24329492
[TBL] [Abstract][Full Text] [Related]
48. A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer.
Flores-Martín JF; Perea F; Exposito-Ruiz M; Carretero FJ; Rodriguez T; Villamediana M; Ruiz-Cabello F; Garrido F; Cózar-Olmo JM; Aptsiauri N
Ann Surg Oncol; 2019 Aug; 26(8):2631-2639. PubMed ID: 31011905
[TBL] [Abstract][Full Text] [Related]
49. Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma.
Zajac M; Boothman AM; Ben Y; Gupta A; Jin X; Mistry A; Sabalos C; Nielsen A; Manriquez G; Barker C; Antal J; Wang P; Patil P; Schechter N; Rebelatto MC; Walker J
Arch Pathol Lab Med; 2019 Jun; 143(6):722-731. PubMed ID: 30457897
[TBL] [Abstract][Full Text] [Related]
50. Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.
Downes MR; Slodkowska E; Katabi N; Jungbluth AA; Xu B
Histopathology; 2020 Jan; 76(2):191-200. PubMed ID: 31243779
[TBL] [Abstract][Full Text] [Related]
51. Overexpression of DAPK1-mediated inhibition of IKKβ/CSN5/PD-L1 axis enhances natural killer cell killing ability and inhibits tumor immune evasion in gastric cancer.
Guo Z; Zhou C; Zhou L; Wang Z; Zhu X; Mu X
Cell Immunol; 2022 Feb; 372():104469. PubMed ID: 35114597
[TBL] [Abstract][Full Text] [Related]
52. Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
Tay WT; Fang YH; Beh ST; Liu YW; Hsu LW; Yen CJ; Liu PY
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244307
[TBL] [Abstract][Full Text] [Related]
53. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape.
Lu C; Liu Z; Klement JD; Yang D; Merting AD; Poschel D; Albers T; Waller JL; Shi H; Liu K
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326167
[TBL] [Abstract][Full Text] [Related]
54. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.
Chen X; Wang K; Jiang S; Sun H; Che X; Zhang M; He J; Wen Y; Liao M; Li X; Zhou X; Song J; Ren X; Yi W; Yang J; Chen X; Yin M; Cheng Y
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35347072
[TBL] [Abstract][Full Text] [Related]
55. Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8
Eissa IR; Mukoyama N; Abdelmoneim M; Naoe Y; Matsumura S; Bustos-Villalobos I; Ichinose T; Miyajima N; Morimoto D; Tanaka M; Fujimoto Y; Sone M; Kodera Y; Kasuya H
Int J Cancer; 2021 Jul; 149(1):214-227. PubMed ID: 33687756
[TBL] [Abstract][Full Text] [Related]
56. Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer.
Stühler V; Maas JM; Bochem J; da Costa IA; Todenhöfer T; Stenzl A; Bedke J
World J Urol; 2019 Sep; 37(9):1773-1784. PubMed ID: 30374610
[TBL] [Abstract][Full Text] [Related]
57. Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy.
Kim R; Hong JY; Lee J; Kwon GY; Jeong BC; Park SH
Cancer Res Treat; 2022 Jul; 54(3):894-906. PubMed ID: 34793662
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer.
Wucherpfennig S; Rose M; Maurer A; Cassataro MA; Seillier L; Morsch R; Hammad E; Baldia PH; Ecke TH; Vögeli TA; Knüchel R; Gaisa NT
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768978
[TBL] [Abstract][Full Text] [Related]
59. PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.
Davick JJ; Frierson HF; Smolkin M; Gru AA
Hum Pathol; 2018 Nov; 81():184-191. PubMed ID: 29969606
[TBL] [Abstract][Full Text] [Related]
60. KRAS G12V mutation upregulates PD-L1 expression via TGF-β/EMT signaling pathway in human non-small-cell lung cancer.
Pan LN; Ma YF; Li Z; Hu JA; Xu ZH
Cell Biol Int; 2021 Apr; 45(4):795-803. PubMed ID: 33325140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
